Literature DB >> 23482262

Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium.

David A Stevenson1, David Little, Linlea Armstrong, Alvin H Crawford, Deborah Eastwood, Jan M Friedman, Tiziana Greggi, Gloria Gutierrez, Kim Hunter-Schaedle, David L Kendler, Mateusz Kolanczyk, Fergal Monsell, Matthew Oetgen, B Stephens Richards, Aaron Schindeler, Elizabeth K Schorry, David Wilkes, David H Viskochil, Feng-Chun Yang, Florent Elefteriou.   

Abstract

BACKGROUND: Neurofibromatosis 1 (NF1) is an autosomal dominant disorder with various skeletal abnormalities occurring as part of a complex phenotype. Tibial dysplasia, which typically presents as anterolateral bowing of the leg with subsequent fracture and nonunion (pseudarthrosis), is a serious but infrequent osseous manifestation of NF1. Over the past several years, results from clinical and experimental studies have advanced our knowledge of the role of NF1 in bone. On the basis of current knowledge, we propose a number of concepts to consider as a theoretical approach to the optimal management of tibial pseudarthrosis.
METHODS: A literature review for both clinical treatment and preclinical models for tibial dysplasia in NF1 was performed. Concepts were discussed and developed by experts who participated in the Children's Tumor Foundation sponsored International Bone Abnormalities Consortium meeting in 2011.
RESULTS: Concepts for a theoretical approach to treating tibial pseudarthrosis include: bone fixation appropriate to achieve stability in any given case; debridement of the "fibrous pseudarthrosis tissue" between the bone segments associated with the pseudarthrosis; creating a healthy vascular bed for bone repair; promoting osteogenesis; controlling overactive bone resorption (catabolism); prevention of recurrence of the "fibrous pseudarthrosis tissue"; and achievement of long-term bone health to prevent recurrence.
CONCLUSIONS: Clinical trials are needed to assess effectiveness of the wide variation of surgical and pharmacologic approaches currently in practice for the treatment of tibial pseudarthrosis in NF1. LEVEL OF EVIDENCE: Level V, expert opinion.

Entities:  

Mesh:

Year:  2013        PMID: 23482262     DOI: 10.1097/BPO.0b013e31828121b8

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  18 in total

1.  Cephalometry in adults and children with neurofibromatosis type 1: Implications for the pathogenesis of sphenoid wing dysplasia and the "NF1 facies".

Authors:  Winnie Cung; Laura A Freedman; Nicholas E Khan; Elaine Romberg; Pamela J Gardner; Carol W Bassim; Andrea M Baldwin; Brigitte C Widemann; Douglas R Stewart
Journal:  Eur J Med Genet       Date:  2015-09-08       Impact factor: 2.708

2.  Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.

Authors:  Jean de la Croix Ndong; David M Stevens; Guillaume Vignaux; Sasidhar Uppuganti; Daniel S Perrien; Xiangli Yang; Jeffry S Nyman; Eva Harth; Florent Elefteriou
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

3.  The reduced osteogenic potential of Nf1-deficient osteoprogenitors is EGFR-independent.

Authors:  S E Tahaei; G Couasnay; Y Ma; N Paria; J Gu; B F Lemoine; X Wang; J J Rios; F Elefteriou
Journal:  Bone       Date:  2017-10-12       Impact factor: 4.398

Review 4.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

5.  FGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation.

Authors:  Matthew R Karolak; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2015-01-23       Impact factor: 6.150

Review 6.  Anterolateral Tibial Bowing and Congenital Pseudoarthrosis of the Tibia: Current Concept Review and Future Directions.

Authors:  Matthew J Siebert; Christopher A Makarewich
Journal:  Curr Rev Musculoskelet Med       Date:  2022-07-16

7.  Identifying Bone Matrix Impairments in a Mouse Model of Neurofibromatosis Type 1 (NF1) by Clinically Translatable Techniques.

Authors:  Rafay Ahmed; Sasidhar Uppuganti; Shrey Derasari; Joshua Meyer; Jacquelyn S Pennings; Florent Elefteriou; Jeffry S Nyman
Journal:  J Bone Miner Res       Date:  2022-07-12       Impact factor: 6.390

8.  Utilization of Whole-Exome Next-Generation Sequencing Variant Read Frequency for Detection of Lesion-Specific, Somatic Loss of Heterozygosity in a Neurofibromatosis Type 1 Cohort with Tibial Pseudarthrosis.

Authors:  Rebecca L Margraf; Chad VanSant-Webb; David Sant; John Carey; Heather Hanson; Jacques D'Astous; Dave Viskochil; David A Stevenson; Rong Mao
Journal:  J Mol Diagn       Date:  2017-05       Impact factor: 5.568

9.  Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.

Authors:  Nandina Paria; Tae-Joon Cho; In Ho Choi; Nobuhiro Kamiya; Kay Kayembe; Rong Mao; Rebecca L Margraf; Gerlinde Obermosser; Ila Oxendine; David W Sant; Mi Hyun Song; David A Stevenson; David H Viskochil; Carol A Wise; Harry K W Kim; Jonathan J Rios
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

10.  Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.

Authors:  Jean de la Croix Ndong; Alexander J Makowski; Sasidhar Uppuganti; Guillaume Vignaux; Koichiro Ono; Daniel S Perrien; Simon Joubert; Serena R Baglio; Donatella Granchi; David A Stevenson; Jonathan J Rios; Jeffry S Nyman; Florent Elefteriou
Journal:  Nat Med       Date:  2014-07-06       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.